The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Author Title Type [ Year(Asc)]
Filters: Author is Karagiannis, Asterios  [Clear All Filters]
2009
Anagnostis, P., Karagiannis A., Tziomalos K., Kakafika A. I., Athyros V. G., & Mikhailidis D. P. (2009).  Adrenal incidentaloma: a diagnostic challenge.. Hormones (Athens). 8(3), 163-84.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Anti-inflammatory effects of fibrates: an overview.. Curr Med Chem. 16(6), 676-84.
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T., & Athyros V. G. (2009).  Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?. Angiology. 60(4), 397-402.
Pagourelias, E. D., Koumaras C., Kakafika A. I., Tziomalos K., Zorou P. G., Athyros V. G., et al. (2009).  Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. Angiology. 60(1), 74-81.
Anagnostis, P., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.. J Clin Endocrinol Metab. 94(8), 2692-701.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Dyslipidemia as a risk factor for ischemic stroke.. Curr Top Med Chem. 9(14), 1291-7.
Karagiannis, A., Hatzitolios A. I., Athyros V. G., Deligianni K., Charalambous C., Papathanakis C., et al. (2009).  Implementation of guidelines for the management of arterial hypertension. The impulsion study.. Open Cardiovasc Med J. 3, 26-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  JUPITER: major implications for vascular risk assessment.. Curr Med Res Opin. 25(1), 133-7.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?. Hellenic J Cardiol. 50(2), 89-91.
Mitsiou, E. K., Tziomalos K., Anagnostis P., Karagiannis A., & Athyros V. G. (2009).  Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.. Hellenic J Cardiol. 50(6), 445-8.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Pleiotropic effects of statins--clinical evidence.. Curr Pharm Des. 15(5), 479-89.
Tziomalos, K., Kakafika A. I., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  The role of statins for the primary and secondary prevention of coronary heart disease in women.. Curr Pharm Des. 15(10), 1054-62.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.. Curr Vasc Pharmacol. 7(3), 264-6.
Tziomalos, K., Athyros V. G., Karagiannis A., Kolovou G. D., & Mikhailidis D. P. (2009).  Triglycerides and vascular risk: insights from epidemiological data and interventional studies.. Curr Drug Targets. 10(4), 320-7.
2008
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?. Expert Opin Investig Drugs. 17(7), 969-72.
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Sambanis, C., Tziomalos K., Kountana E., Kakavas N., Zografou I., Balaska A., et al. (2008).  Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes.. Acta Diabetol. 45(1), 23-30.
Athyros, V. G., Tziomalos K., Kakafika A. I., Koumaras H., Karagiannis A., & Mikhailidis D. P. (2008).  Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.. Am J Cardiol. 101(4), 483-5.
Athyros, V. G., Kakafika A. I., Karagiannis A., Koragiannis A., Mikhailidis D. P., & Mikhalidis D. P. (2008).  Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.. Am J Cardiol. 101(11), 1679-80.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Paraskevas K. I., Tziomalos K., Anagnostis P., et al. (2008).  Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.. Curr Med Res Opin. 24(6), 1593-9.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2008).  Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. Expert Opin Ther Targets. 12(7), 809-20.
Karagiannis, A., Mikhailidis D. P., Tziomalos K., Kakafika A. I., & Athyros V. G. (2008).  Has the time come for a new definition of microalbuminuria?. Curr Vasc Pharmacol. 6(2), 81-3.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.